Related Experiment Videos
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
François Bertucci1, Pascal Finetti2, Delphine Perrot3
1Department of Molecular Oncology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, UMR1068 Inserm, Marseille, France; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, Marseille, France; French Sarcoma Group, Lyon, France.
Oncoimmunology
|April 14, 2017
Summary
High programmed death-ligand 1 (PDL1) expression in soft-tissue sarcomas (STS) predicts shorter metastasis-free survival. PD1/PDL1 blockade may improve survival in PDL1-high STS by enhancing antitumor immunity.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Soft-tissue sarcomas (STS) are rare, aggressive tumors with limited treatment options.
- Immune checkpoint inhibitors targeting PD1/PDL1 show promise in solid tumors.
- PDL1 expression and its prognostic role in STS are poorly understood.
Purpose of the Study:
- To analyze PDL1 mRNA expression in a large cohort of STS.
- To correlate PDL1 expression with clinicopathological variables and metastasis-free survival (MFS).
- To explore the potential of PD1/PDL1 blockade in STS treatment.
Main Methods:
- Retrospective analysis of PDL1 mRNA expression in 758 STS samples using DNA microarrays and RNAseq.
- Correlation analysis with clinicopathological features and MFS.
- Multivariate prognostic analysis.
Main Results:
- PDL1 expression was heterogeneous, with 41% of samples classified as PDL1-high.
- PDL1-high tumors were more frequent in leiomyosarcomas and liposarcomas, often showing complex genetic profiles and high-risk CINSARC signatures.
- PDL1-high expression was independently associated with shorter MFS.
- Analysis suggested an efficient but exhausted cytotoxic T-cell response in PDL1-high tumors.
Conclusions:
- PDL1 expression refines metastatic relapse prediction in operated localized STS.
- PD1/PDL1 blockade therapy holds potential for improving survival in PDL1-high STS by reactivating T cells and boosting antitumor immunity.